Acurx Expands Patent Portfolio with New Grants in Japan and Mexico
Event summary
- Acurx Pharmaceuticals received new patents from Japan and Mexico for its DNA Polymerase IIIC inhibitors, covering compositions-of-matter, methods of use, and pharmaceutical compositions.
- The company now holds six U.S. patents and ten international patents across multiple countries, including Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico.
- Acurx's lead product candidate, ibezapolstat, is Phase 3 ready for treating C. difficile Infection (CDI) pending appropriate financing.
- FDA guidance suggests a single Phase 3 trial could support an NDA filing for both treatment and reduction of recurrence of CDI.
The big picture
Acurx's new patents strengthen its intellectual property position in key markets, supporting its pipeline of antibiotics targeting difficult-to-treat infections. The company's focus on DNA Polymerase IIIC inhibitors positions it to address serious infections like C. difficile and MRSA, where existing treatments often fall short. With FDA guidance suggesting a streamlined approval pathway for ibezapolstat, Acurx is poised to potentially transform the treatment paradigm for these conditions.
What we're watching
- Patent Strategy
- How Acurx will leverage its expanded patent portfolio to strengthen market positioning and licensing opportunities.
- Clinical Execution
- Whether the company can secure financing and initiate Phase 3 trials for ibezapolstat as planned.
- Regulatory Pathway
- The pace at which FDA will review and potentially approve ibezapolstat based on a single Phase 3 trial.